Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project).
The Coronary Drug Project, conducted during 1966 to 1974, was a randomized, double-blind, placebo-controlled trial of 5 lipid-modifying agents in 8,341 men with previous myocardial infarction. Among the 5 drug treatment regimens, only niacin significantly reduced the risk of (1) cardiovascular events during a mean follow-up of 6.2 years and (2) total mortality during 6.2 years with study treatment plus an additional 9 years of post-trial follow-up (Figure 1). Cardiovascular and total mortality outcomes in the niacin and placebo groups are presented by baseline glycemic status and by change in glycemic status from baseline to year 1.
Canner
Paul L
PL
Maryland Medical Research Institute, 600 Wyndhurst Avenue, Baltimore, MD 21210, USA. plcanner@juno.com
Furberg
Curt D
CD
Terrin
Michael L
ML
McGovern
Mark E
ME
D001786:Blood Glucose / Q000378:metabolism; D005431:Florida / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008297:Male; D008396:Maryland / Q000453:epidemiology; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000401:mortality*; D009525:Niacin / Q000008:administration & dosage*; D009657:North Carolina / Q000453:epidemiology; D016016:Proportional Hazards Models; D016032:Randomized Controlled Trials as Topic
D001786:Blood Glucose; D000960:Hypolipidemic Agents; D009525:Niacin